Category: Uncategorized

In Labiotech’s deep dive on emerging prostate cancer treatments, the standout innovation comes from Jonas Båtelson, CEO of Curacell, explains that CC‑38 is designed specifically to overcome the immunosuppressive “cold tumor” environment that makes these cancers resistant to immunotherapy. By reviving exhausted T cells and restoring their ability to recognise and attack tumors, CuraCell’s platform aims to turn cold tumors hot and unlock responses where other immunotherapies fail.

The article highlights CuraCell’s ongoing Phase I/IIa trial in Frankfurt and underscores Jonas’s central message: the company has cracked a key challenge in solid‑tumor immunotherapy — revitalising naturally occurring T cells so they can persist, function, and kill cancer cells inside highly suppressive tumor microenvironments.

Read the full article here. 

In the latest Base to Base biotech podcast, Dicot Pharma’s CEO, Elin Trampe tells Jim Cornall how the company is developing LIB‑01, positioned as the first major innovation in erectile dysfunction treatment in 30 years. Unlike Viagra or Cialis, LIB‑01 uses a completely different mechanism of action, enabling treatment for a broader population of men, including those who cannot take PDE5 inhibitors.

Trampe confirms that Dicot has recently received regulatory clearance to begin Phase IIb trials in the US, with EU trials also about to start. The treatment is designed as a three‑dose regimen that provides spontaneous erectile function for up to eight weeks, removing the need for planning around sexual activity and aiming to improve intimacy and quality of life for couples.

Listen to the podcast here. 

Affibody's Fredrik Frejd recently spoke with Clinical Supply Leader about why radiopharmaceutical logistics operate on a knife‑edge. He compared transporting radioactive drugs to “moving melting ice cubes,” where every dose must arrive at precisely the right activity — and any disruption, including a patient missing their appointment, can waste an entire batch.

Frejd outlined how decay profiles dictate everything from manufacturing location to scheduling flexibility. Short half‑lives demand production near trial sites, while longer‑lived isotopes like actinium‑225 allow global shipping but remain in critically short supply. Consistent dosimetry, cross‑border transport rules, and uneven regulatory frameworks add further complexity.

The field now faces a strategic choice: standardised dosing that speeds trials, or personalised dosimetry that could unlock more precise and effective radiotherapeutics. “It’s a delicate balance,” Frejd said — one that will shape how widely patients can access these emerging treatments.

Read the full article here. 

Albus Health recently featured in Healio’s coverage of new ERS 2026 data showing that higher nocturnal cough rates are linked to worsening asthma symptoms in adults with severe, uncontrolled disease.

In a year‑long pilot study from Leiden University Medical Center, patients using the Albus Home contactless bedside device showed exceptionally high adherence, enabling researchers to capture continuous, clinical‑grade nighttime data. A five-fold rise in nocturnal cough was associated with significantly higher odds of worse asthma symptoms for up to three days afterwards — offering an objective signal of deteriorating control that traditional tools often miss.

The study underscores the limitations of intermittent assessments and patient‑reported diaries, and highlights how passive, burden‑free monitoring can reveal day‑to‑day changes in disease activity. Researchers also noted substantial variation between patients, pointing to future opportunities to identify who benefits most from nocturnal cough tracking and how combining cough with other physiological signals could deepen clinical insight.

As Albus advances its next‑generation platform — now capturing heart rate, sleep patterns, inhalation/exhalation duration and environmental factors — these findings reinforce the potential of continuous, contactless monitoring to transform how severe asthma is understood and managed.

CuraCell Oncology and One‑carbon Therapeutics were highlighted in Pharmaceutical Technology’s recent analysis of why Nordic biopharma innovation is outpacing commercial returns — and what that means for the region’s next generation of therapeutics.

The piece notes that while the Nordics continue to produce scientifically differentiated platforms, many emerging biotechs are struggling to secure the scale‑up capital required to translate that innovation into late‑stage development. Investors are increasingly selective, favouring companies with clear clinical rationale, strong translational data, and mechanisms capable of delivering meaningful patient impact.

Against this backdrop, CuraCell’s personalised TIL platform and One‑Carbon’s precision oncology approach exemplify the type of science‑driven, clinically anchored innovation still attracting attention. Both companies operate in areas where global demand for novel cancer therapies remains high, and where differentiated biology can help overcome the funding bottleneck facing the broader Nordic ecosystem.

The article frames the challenge as one of momentum: Nordic biotechs are generating world‑class ideas, but only those with robust clinical strategies and compelling value stories will break through the capital constraints shaping the region’s investment landscape.

Read the full article here. 

Northway Biotech founder Vladas Algirdas Bumelis spoke to European Biotechnology about the company’s €61m investment in a new Vilnius manufacturing center built specifically for cell therapies and personalized medicines. The story explores how the CDMO is positioning itself at the forefront of a shifting pharmaceutical model, one where entire manufacturing processes may be dedicated to a single patient, and where speed, segregation and supply‑chain consolidation become critical enablers for next‑generation therapies. With ten production lines currently undergoing qualification and manufacturing authorisation expected within six months, Northway is already onboarding development projects and preparing clients to transition into GMP as soon as approval lands.

Bumelis outlines how the facility’s design is intended to remove traditional bottlenecks in CAR‑T and gene therapy supply chains. The piece highlights Lithuania’s strategic backing, including €48m in national development bank financing, and frames the plant as a cornerstone of the country’s ambition to grow life sciences to 5% of GDP by 2030. Together, the investment, infrastructure and co‑located capabilities illustrate a broader bet: that industrial‑scale personalised medicine will move out of hospital settings and into purpose‑built CDMOs capable of running many small processes in parallel.

Read the full story here.

BriefGlance reported on a new study unveiled at ERS 2026 showing that Albus Health’s contactless, AI‑powered bedside device can reliably predict worsening asthma symptoms simply by listening for nocturnal cough. Researchers from Leiden University Medical Centre found that every five‑fold increase in nighttime cough was linked to a 1.5x higher chance of worse symptoms the next day, with the predictive window extending up to three days. With patients monitored for a median of 9.5 hours per night and near‑perfect adherence, the study highlights how passive, ambient monitoring can deliver objective, continuous data that transforms both clinical care and drug development.

The findings mark a major shift away from subjective patient reporting and toward proactive, personalised asthma management. By capturing high‑fidelity cough data without requiring patients to wear or do anything, Albus Health is helping clinicians intervene earlier, improving trial endpoints, and reducing patient burden, signalling a new era for digital biomarkers in respiratory disease.

Read the full article here.

Racura Oncology CEO Daniel Tillett and Cereno Scientific CEO Sten Sörensen spoke to David Wild for In Vivo’s deep dive into the growing movement to resurrect shelved or abandoned drugs. The story explores how both companies are mining pharma’s “graveyard” of discontinued assets — not as a last resort, but as a strategic shortcut to reach patients faster by repurposing molecules with known safety profiles and overlooked mechanisms.

Tillett describes how Racura revived bisantrene, a decades‑old anticancer drug, by uncovering its ability to stabilize G‑quadruplex DNA structures and suppress MYC, a mechanism that had been missed in earlier development. Sörensen outlines Cereno’s work repurposing a 60‑year‑old epilepsy drug for pulmonary arterial hypertension, leveraging its epigenetic effects to modify disease progression. Together, their programs illustrate a broader shift: biotech innovators are increasingly turning to abandoned compounds as fertile ground for new therapies, provided the biology is strong and the clinical rationale is clear.

Read the full story here.

CuraCell Oncology was featured in Labiotech’s coverage of NLS Days 2026, where next‑generation cell therapies and epigenetic innovation dominated the conversation among Nordic biotech leaders.

The meeting highlighted how the region’s oncology developers are pushing toward more precise, mechanism‑driven treatments. CuraCell’s progress in advancing personalised TIL therapies stood out within this landscape, with the company emphasising its focus on scalability, potency and faster turnaround times for solid‑tumour indications.

Across the conference, investors and industry experts pointed to a growing appetite for platforms capable of reshaping treatment paradigms rather than incrementally improving existing options. CuraCell’s approach — combining deep tumour‑targeting expertise with a commitment to manufacturability — reflects the type of innovation that continues to draw attention as Nordic biotech matures.

The article frames NLS Days 2026 as a snapshot of a sector shifting toward therapies that modify disease biology at its core. CuraCell’s work sits firmly within that momentum, underscoring its role in the region’s next wave of oncology breakthroughs.

Read the full article here. 

Millie Nelson, senior editor for Partnering and Investment at BioXconomy, sat down with HaemaLogiX CEO Chris Baldwin to unpack the Australian biotech’s transition from private promise to public potential as it prepares for an IPO. Baldwin reflects on the unexpected momentum behind the company’s precision immunotherapy pipeline, built around the novel KMA and LMA antigens, and why market transparency, investor accountability and clinical discipline are central to HaemaLogiX’s strategy as it moves toward Phase II inflection points.

Nelson’s piece situates HaemaLogiX within a wider wave of next‑generation oncology innovation, highlighting how companies like CuraCell are also redefining the path to market with platforms designed to deliver more targeted, scalable and immune‑preserving cancer therapies. Together, these emerging players illustrate a shift in how early‑stage biotechs are approaching public markets: not with hype, but with differentiated science, clear clinical rationale and a focus on mechanisms that can meaningfully change patient outcomes.

To read the full story on HaemaLogiX’s journey — and the market forces shaping its next chapter — access the complete article here.